In addition, the siRNA targeting NAT10 reduced the IC50 of gemcitabine in Capan-1 cells from 76.28μM to 23.34μM (Figure 9G), indicating that NAT10 knockdown significantly reduced the resistance of pancreatic ductal adenocarcinoma cells to gemcitabine. The gene discussed is NAT10; the disease is pancreatic ductal adenocarcinoma.